Study of Adoptive Transfer of iNKT Cells Combined With TACE to Treat Advanced HCC
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is a common disease with high mortality. More than 80%
patients are first diagnosed with late-stage and unresectable, their effective drugs and
treatments are very limited. invariant Natural Killer T (iNKT) cell exhibit antitumor
activity against malignant tumors through producing high levels of cytokines. iNKT cells are
abundant in the liver, but defect in liver cancer development. iNKT cells can express homing
receptors licensing them specifically to migrate liver, then play key antitumor immunity. We
already did a phase I study of autologous infusion of iNKT cells in the treatment of patients
with advanced HCC. Safety and feasibility of iNKT infusion was proved. The purpose of this
study is to verify the effectiveness of iNKT cells infusion combined with transcatheter
arterial chemoembolization (TACE) in treatment of advanced HCC.